Here's why the Imugene share price just got a boost

Imugene's latest announcement is rallying up investors.

| More on:
Person pointing at an increasing blue graph which represents a rising share price.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Key points

  • Imugene shares surge 4.24% to 17.2 cents 
  • The company has dosed its first patient in the phase 1 clinical trial of oncolytic virus, CF33-hNIS 
  • The study is aiming to recruit 100 patients across 10 trial sites in the United States and Australia 

The Imugene Limited (ASX: IMU) share price has shot up during early afternoon trade.

This comes after the company announced an update on its phase 1 clinical trial of its novel cancer-killing virus, CF33-hNIS.

Developed by City of Hope, the oncolytic virus has demonstrated in shrinking solid tumours in preclinical laboratory and animal trials. This includes colon, lung, breast, ovarian and pancreatic cancer tumours.

City of Hope is one of the largest cancer research and treatment organizations in the United States.

At the time of writing, the clinical stage immuno-oncology company's shares are 4.24% higher to 17.2 cents.

Imugene commences Vaxinia study

In its release, Imugene advised it has dosed the first patient in the phase 1 clinical trial of CF33-hNIS (Vaxinia).

This has stirred up excitement among investors, sending the Imugene share price higher.

Management noted the primary goal of the study is to evaluate the safety of CF33-hNIS when used in people with advanced solid tumours.

At first, a low dose of CF33-hNIS will be administered to cancer patients with metastatic or advanced solid tumours. This will be for those who have had at least two prior lines of standard of care treatment.

The investigational treatment will be delivered either as an injection directly into tumours or intravenously.

Once patients have been treated with CF33-hNIS and acceptable safety has been demonstrated, new study participants will progress to the next stage.

Those volunteers will receive the experimental oncolytic virus in combination with the immunotherapy pembrolizumab. The latter is an engineered antibody that improves the immune system's ability to fight cancer-causing cells.

The study aims to recruit 100 patients across approximately 10 sites in the United States and Australia.

The trial is anticipated to run for approximately 24 months and will be funded from Imugene's existing cash reserves.

Imugene managing director and CEO Leslie Chong commented:

The dosing of the first patient in our Vaxinia study is a significant milestone for Imugene and clinicians faced with the challenge of treatment for metastatic advanced solid tumours.

Professor Yuman Fong and the City of Hope team have provided outstanding research. In addition to the positive preclinical results, we're incredibly eager to unlock the potential of Vaxinia and the oncolytic virotherapy platform.

Imugene share price snapshot

Despite today's gains, the Imugene share price has been on a trending decline over the past 12 months. Its shares are down almost 50%, with year to date losses of around 57%.

The company's shares hit a 52-week low of 15 cents last week, before moving in circles.

Based on the current price, Imugene has a market capitalisation of roughly $965.05 million.

Should you invest $1,000 in CSL right now?

Before you buy CSL shares, consider this:

Motley Fool investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now... and CSL wasn't one of them.

The online investing service he’s run for over a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

And right now, Scott thinks there are 5 stocks that may be better buys...

See The 5 Stocks *Returns as of 30 April 2025

Motley Fool contributor Aaron Teboneras has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Two doctors wearing white coats look closely at a medical imaging x-ray as the share prices of ASX 200 healthcare shares improve in FY23
Healthcare Shares

Pro Medicus shares climb 33% in less than a month, have I missed the dip?

Pro Medicus shares have soared. Is it the right time to invest?

Read more »

Man with rocket wings which have flames coming out of them.
Share Gainers

Guess which ASX All Ords share just rocketed 19% on BIG news

Investors are sending this ASX All Ords share flying on Monday. But why?

Read more »

A young male ASX investor raises his clenched fists in excitement because of rising ASX share prices today
Healthcare Shares

Why is this ASX All Ords stock surging 14% today?

This stock is starting the week strongly. But why? Let's find out.

Read more »

A man has a surprised and relieved expression on his face. as he raises his hands up to his face in response to the high fluctuations in the Galileo share price today
Healthcare Shares

Guess which ASX All Ords stock is rocketing 58% on big US news

What is getting investors excited today? Let's find out.

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

3 reasons to buy this quality ASX 200 healthcare share today

A leading expert expects this outperforming ASX 200 healthcare share will keep running hot.

Read more »

A woman reclines in a comfortable chair while she donates blood holding a pumping toy in one hand and giving the thumbs up in the other as she is attached to a medical machine to collect her blood donation.
Healthcare Shares

Brokers tip 4 ASX 200 healthcare shares to buy now

Healthcare is a defensive sector that can provide useful cover for investors when the market is volatile.

Read more »

Shot of a scientist using a computer while conducting research in a laboratory.
Healthcare Shares

How Trump's tariffs have created 'upside potential' for CSL shares

A leading expert says CSL shares are now looking ‘cheap’.

Read more »

Shot of a young scientist looking stressed out while working on a computer in a lab.
Healthcare Shares

Telix shares crash 8% on US FDA blow

This high-flying stock has been hit with some bad news.

Read more »